Concepedia

Author

Oleksandra Stasyshyn

Institute of Blood Pathology and Transfusion Medicine of the National Academy of Medical Sciences of UkraineORCID

Also Known As

O Stasyshyn, O. B. Datsenko, O. Stasyshyn, O. V. Stasyshyn, O.V. Stasyshyn, Oleksandra Stasyshyn, Stasyshyn O, Олександра Стасишин

57

Publications

1.4K

Citations

16

H-Index

12

Concepts

All Affiliations

Institute of Blood Pathology and Transfusion Medicine of the National Academy of Medical Sciences of UkraineInstytut Hematologii i TransfuzjologiChristian Medical College, VelloreNational Health Laboratory ServiceAzienda Ospedaliero-Universitaria Careggi
OS

About

Oleksandra Stasyshyn is an author at Institute of Blood Pathology and Transfusion Medicine of the National Academy of Medical Sciences of Ukraine specializing in hematology, medicine, and thrombosis.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

3

3

149

2

Health Sciences

1

1

57

3

Medical Laboratory Science

1

1

17

4

Pathology

1

1

57

5

Pharmacology

1

1

17

Oleksandra Stasyshyn

×

20

Publications

1.1K

Citations

15

H-Index

YearCitations

Pegylated, full-length, recombinant factor VIII for prophylactic and on-demand treatment of severe hemophilia A

Barbara A. Konkle, Oleksandra Stasyshyn, Pratima Chowdary,

Blood

2015

250

Randomized comparison of prophylaxis and on‐demand regimens with <scp>FEIBA NF</scp> in the treatment of haemophilia A and B with inhibitors

Sandra Vallin Antunes, Srilatha Tangada, Oleksandra Stasyshyn,

Haemophilia

2013

112

Phase 3 Trial of Concizumab in Hemophilia with Inhibitors

Tadashi Matsushita, Amy D. Shapiro, Aby Abraham,

New England Journal of Medicine

2023

91

Efficacy and safety of rVIII-SingleChain: results of a phase 1/3 multicenter clinical trial in severe hemophilia A

Johnny Mahlangu, Kazimierz Kuliczkowski, Faraizah Abdul Karim,

Blood

2016

85

Extended half‐life pegylated, full‐length recombinant factor <scp>VIII</scp> for prophylaxis in children with severe haemophilia A

Eric S. Mullins, Oleksandra Stasyshyn, María Román,

Haemophilia

2016

79

Fitusiran prophylaxis in people with severe haemophilia A or haemophilia B without inhibitors (ATLAS-A/B): a multicentre, open-label, randomised, phase 3 trial

Alok Srivastava, Savita Rangarajan, Kaan Kavaklı,

The Lancet Haematology

2023

75

Rurioctocog alfa pegol PK-guided prophylaxis in hemophilia A: results from the phase 3 PROPEL study

Robert Klamroth, Jerzy Windyga, Vlad C. Radulescu,

Blood

2020

71

Phase 3 study of recombinant von Willebrand factor in patients with severe von Willebrand disease who are undergoing elective surgery

Flora Peyvandi, J.‐D. Wang, Oleksandra Stasyshyn,

Journal of Thrombosis and Haemostasis

2018

70

Safety and efficacy of a glycoPEGylated rFVIII (turoctocog alpha pegol, N8-GP) in paediatric patients with severe haemophilia A

Sandrine Meunier, Jayanthi Alamelu, S. Ehrenforth,

Thrombosis and Haemostasis

2017

57

Pharmacokinetics, efficacy and safety of BAX326, a novel recombinant factor IX: a prospective, controlled, multicentre phase I/III study in previously treated patients with severe (FIX level &lt;1%) or moderately severe (FIX level ≤2%) haemophilia B

Jerzy Windyga, Toshko Lissitchkov, Oleksandra Stasyshyn,

Haemophilia

2013

48

Page 1